Merck's Q2 2007 earnings call highlights strong performance, driven by strong sales growth in key products like SINGULAIR, VYTORIN, ZETIA, and GARDASIL.  Management raised guidance for full-year EPS, indicating confidence in continued momentum.  The call also detailed upcoming regulatory actions for Isentress and MK-0524A, suggesting continued investment in new drug development.
[1]
